Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction

Journal of Molecular Recognition

Volumn 23, Issue 1, 2010, Pages 65-73

  Buchwald, Peter ^a   Margolles Clark, Emilio ^a   Kenyon, Norma S ^a   Ricordi, Camillo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Binding free energy; CD40 ligand; Costimulation; Immune suppression; Protein protein interaction

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; COLORING AGENT; SURAMIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HUMAN; IC 50; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ANTIGENS, CD40; B-LYMPHOCYTES; CD40 LIGAND; CELL PROLIFERATION; COLORING AGENTS; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SURAMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73249129041     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.969     Document Type: Article

References (54)

1. Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. 2005. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation block-ade. J. Pept. Res. 65: 591-604.
2. Arkin MR, Wells JA. 2004. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3: 301-317.
3. Bajorath J. 1998. Detailed comparison of two molecular models of the human CD40 ligand with an x-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J. Biol. Chem. 273: 24603-24609.
4. Barbé-Tuana FM, Klein D, Ichii H, Berman DM, Coffey L, Kenyon NS, Ricordi C, Pastori RL. 2006. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes 55: 2437-2445.
5. Bogan AA, Thorn KS. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280: 1-9.
6. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. 2004. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J. Clin. Invest. 114: 979-987.
7. Buchwald P. 2008. Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids 73: 193-208.
8. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, Bello-Laborn H, Hacquoil B, Strobert E, Gangappa S, Weber CJ, Pearson TC, Rajotte RV, Larsen CP. 2006. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat. Med. 12: 304-306.
9. Che Y, Brooks BR, Marshall GR. 2006. Development of small molecules designed to modulate protein-protein interactions. J. Comput. Aided Mol. Des. 20: 109-130.
10. Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108.
11. Deambrosis I, Lamorte S, Giaretta F, Tei L, Biancone L, Bussolati B, Camussi G. 2009. Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154. J. Mol. Med. 87: 181-197.
12. Denizli A, Piskin E. 2001. Dye-ligand affinity systems. J. Biochem. Biophys. Methods 49: 391-416.
13. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. 1985. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107: 3902-3909.
14. Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS. 2000. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study. J. Infect. Dis. 182: 607-610.
15. Ehrlich P. 1911. Aus theorie und praxis der chemotherapie. (in German) Folia Serologica 7: 697-714.
16. Ely KR, Li C. 2002. Structurally adaptive hot spots at a protein interaction interface on TRAF3. J. Mol. Recognit. 15: 286-290.
17. Fecteau JF, Ne ́ron S. 2003. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J. Immunol. 171: 4621-4629.
18. Feng BY, Shoichet BK. 2006. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1: 550-553.
19. Fletcher S, Hamilton AD. 2006. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J.R. Soc. Interface 3: 215-233.
20. Fournel S, Wieckowski S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. 2005. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat. Chem. Biol. 1: 377-382.
21. Fuller JC, Burgoyne NJ, Jackson RM. 2008. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today Epub.
22. Hajduk PJ. 2006. Fragment-based drug design: how big is too big? J. Med. Chem. 49: 6972-6976.
23. Hershberger SJ, Lee SG, Chmielewski J. 2007. Scaffolds for blocking protein-protein interactions. Curr. Top. Med. Chem. 7: 928-942.
24. Hopkins AL, Groom CR, Alex A. 2004. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9: 430-431.
25. Hunger K. 2003. Industrial Dyes. Chemistry, Properties, Applications 3rd edn. Wiley-VCH: Weinheim; 660.
26. Jumper MD, Nishioka Y, Davis LS, Lipsky PE, Meek K. 1995. Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J. Immunol. 155: 2369-2378.
27. Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu YM. 2001. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9: 321-329.
28. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C. 1999. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA. 96: 8132-8137.
29. Kitagawa M, Goto D, Mamura M, Matsumoto I, Ito S, Tsutsumi A, Sumida T. 2005. Identification of three novel peptides that inhibit CD40-CD154 interaction. Mod. Rheumatol. 15: 423-426.
30. Margolles-Clark E, Jacques-Silva MC, Ganesan L, Umland O, Kenyon NS, Ricordi C, Berggren P-O, Buchwald P. 2009. Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. Biochem. Pharmacol. 77: 1236-1245.
31. McGovern SL, Caselli E, Grigorieff N, Shoichet BK. 2002. A common mechanism underlying promiscuous inhibitors from virtual and highthroughput screening. J. Med. Chem. 45: 1712-1722.
32. Miyazawa M, Ito Y, Kosaka N, Nukada Y, Sakaguchi H, Suzuki H, Nishiyama N. 2008. Role of TNF-alpha and extracellular ATP in THP-1 cell activation following allergen exposure. J. Toxicol. Sci. 33: 71-83.
33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19: 1639-1662.
34. Neugebauer A, Hartmann RW, Klein CD. 2007. Prediction of proteinprotein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem. 50: 4665-4668.
35. Ono M, Wada Y, Wu Y, Nemori R, Jinbo Y, Wang H, Lo KM, Yamaguchi N, Brunkhorst B, Otomo H, Wesolowski J, Way JC, Itoh I, Gillies S, Chen LB. 1997. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nat. Biotechnol. 15: 343-348.
36. Overington JP, Al-Lazikani B, Hopkins AL. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5: 993-996.
37. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22: 307-328.
38. Reynolds CH, Bembenek SD, Tounge BA. 2007. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 17: 4258-4261.
39. Roterman I, No KT, Piekarska B, Kaszuba J, Pawlicki R, Rybarska J, Konieczny L. 1993. Bis azo dyes studies on the mechanism of complex formation with IgG modulated by heating or antigen binding. J. Physiol. Pharmacol. 44: 213-232.
40. Schlein M, Ludvigsen S, Olsen HB, Andersen AS, Danielsen GM, Kaarsholm NC. 2001. Properties of small molecules affecting insulin receptor function. Biochemistry 40: 13520-13528.
41. Schonbeck U, Libby P. 2001. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58: 4-43.
42. Shoichet BK. 2006. Screening in a spirit haunted world. Drug Discov. Today 11: 607-615.
43. Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, Naismith JH, Thomas D. 1998. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. 7: 1124-1135.
44. Sousa SF, Fernandes PA, Ramos MJ. 2006. Protein-ligand docking: current status and future challenges. Proteins 65: 15-26.
45. Stopa B, Gorny M, Konieczny L, Piekarska B, Rybarska J, Skowronek M, Roterman I. 1998. Supramolecular ligands: monomer structure and protein ligation capability. Biochimie 80: 963-968.
46. Strebhardt K, Ullrich A. 2008. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8: 473-480.
47. Tsopelas C, Sutton R. 2002. Why certain dyes are useful for localizing the sentinel lymph node. J. Nucl. Med. 43: 1377-1382.
48. Vincenti F, Luggen M. 2007. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu. Rev. Med. 58: 347-358.
49. Wagner DH Jr, Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. 2002. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc. Natl. Acad. Sci. USA. 99: 3782-3787.
50. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS. 2006. A critical assessment of docking programs and scoring functions. J. Med. Chem. 49: 5912-5931.
51. Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
52. Wierenga KJ, Lai K, Buchwald P, Tang M. 2008. High-throughput screening for human galactokinase inhibitors. J. Biomol. Screen. 13: 415-423.
53. Wilbur DS. 2003. Formation of sulfonamide bonds through reaction of dyes with serum proteins. J. Nucl. Med. 44: 1540-1541.
54. Zheng Z, Carter MB, Liao Y, Sun L, Kirkovsky L, Mrose S, Hsu Y-M, Thomas D, Shipps GW Jr, Jindal S, Lenz GR, Nash HM. Novel CD40: CD154 binding interruptor compounds and use thereof to treat immunological complications. US Patent 7,173,046 B2, February 6, 2007.